468 related articles for article (PubMed ID: 22818904)
1. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
[TBL] [Abstract][Full Text] [Related]
2. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
4. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
Fujita K; Yuzawa M; Mori R
Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
[TBL] [Abstract][Full Text] [Related]
5. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
6. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
[TBL] [Abstract][Full Text] [Related]
7. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
[TBL] [Abstract][Full Text] [Related]
9. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
10. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
11. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
[TBL] [Abstract][Full Text] [Related]
12. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
[TBL] [Abstract][Full Text] [Related]
13. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
Li L; Yuan F; Xu GZ; Wang WJ
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
[TBL] [Abstract][Full Text] [Related]
14. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
[TBL] [Abstract][Full Text] [Related]
15. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
[TBL] [Abstract][Full Text] [Related]
16. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
17. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
Lai TY; Wong RL; Chan WM
Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
[TBL] [Abstract][Full Text] [Related]
19. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.
Iwase T; Yokouchi H; Kitahashi M; Kubota-Taniai M; Baba T; Yamamoto S
Biomed Res Int; 2020; 2020():3190136. PubMed ID: 32908883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
